Oral Session

Oral Session 3-10B MM: Novel therapeutic approaches

Sun. Oct 14, 2018 9:40 AM - 10:40 AM No.10 (Osaka International Convention Center, 10F 1009)

Chair: Masuzu Ueda (Division of Hematology, Depaertment of Internal Medicine, Jichi Medical University, Japan)

+Add all to schedule

[OS3-10B-1] The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease

Masahiro Hiasa^1,2, Jumpei Teramachi^1,3, Hirofumi Tenshin^1,2, Kotaro Tanimoto^1,2, Bat-Erdene Ariunzaya¹, Ashtar Mohannad^1,2, Masami Iwasa¹, Takeshi Harada¹, Shingen Nakamura¹, Hirokazu Miki⁴, Kimiko Sogabe¹, Masahiro Oura¹, Shiro Fujii¹, Kumiko Kagawa¹, Asuka Oda¹, Itsuro Endo⁵, Eiji Tanaka², Toshio Matsumoto⁶, Masahiro Abe¹ (1.Department of Hematology, Endocrinology and Metabolism, Tokushima Univ., Tokushima, Japan, 2.Department of Orthodontics and Dentofacial Orthopedics, Tokushima Univ., Tokushima, Japan, 3.Department of Histology and Oral Histology,Tokushima Univ., Tokushima, Japan, 4.Transfusion Medicine and Cell Therapy, Tokushima Univ., Tokushima, Japan, 5.Department of Chronomedicine, Tokushima Univ., Tokushima, Japan, 6.Fujii Memorial Institute of Medical Sciences, Tokushima Univ., Tokushima, Japan)

[OS3-10B-2] Bi-allelic loss of FAM46C by CRISPR/CAS9 system enhances myeloma cell growth

Jo Kanasugi¹, Ichiro Hanamura¹, Akinobu Ota², Sivasundaram Karnan², Shohei Mizuno¹, Kaori Uchino¹, Ayano Nakamura¹, Soichi Takasugi¹, Tomohiro Horio¹, Mineaki Goto¹, Mayuko Goto¹, Miyuki Takahashi¹, Hidesuke Yamamoto¹, Masaya Watarai¹, Hidetsugu Mihara¹, Takayuki Nakayama⁴, Hidehumi Kato⁵, Susumu Suzuki³, Yoshihisa Kodera⁶, Yoshitaka Hosokawa², Ryuzo Ueda³, Akiyoshi Takami¹ (1.Division of Hematology, Aichi Medical University, Nagakute, Japan, 2.Department of Biochemistry, Aichi Medical University, Nagakute, Japan, 3.Department of Tumor Immunology, Aichi Medical University, Nagakute, Japan, 4.Central Clinical Laboratory, Aichi Medical University, Nagakute, Japan, 5.Blood Transfusion Department, Aichi Medical University Hospital, Nagakute, Japan, 6.Department of Promotion for Blood and Marrow Transplantation)

[OS3-10B-3] A glycolytic gene HK2 as a therapeutic target of myeloma cells in hypoxic microenvironment

Sho Ikeda, Akihiro Kitadate, Fumito Abe, Naoto Takahashi, Hiroyuki Tagawa (Department of Hematology, Nephrology and Rheumatology, Akita University, Akita, Japan.)

[OS3-10B-4] Combination of venetoclax and Mcl-1 inhibitor shows an excellent cytotoxic activity against myeloma

Akira Yoshida¹, Takuya Ogawa², Hideki Yagi² (1.Dept of Hematology, International University of Health and Welfare, 2.Dept of Pharmacy, International University of Health and Welfare, Japan)

[OS3-10B-5] A novel ER-stress sensor inhibitor, KIRA8, is a potential therapeutic agent for human myeloma cells

Shinobu Tamura¹, Yusuke Yamashita¹, Shuhei Morita², Takashi Akamizu², Takashi Sonoki¹ (1.Hematol./Oncol., Wakayama Med. Univ., Wakayama, Japan, 2.First Dep. of Intern. Med., Wakayama Med. Univ., Wakayama, Japan)

[OS3-10B-6] Impact of denervation-induced paralysis and mechanical unloading on tumor expansion in myeloma

Kotaro Tanimoto^1,2, Masahiro Hiasa^1,2, Hirofumi Tenshin¹, Jumpei Teramachi⁴, Asuka Oda³, Ashtar Mohannad¹, Bat-Erdene Ariunzaya³, Masami Iwasa³, Kimiko Sogabe³, Masahiro Oura³, Takeshi Harada³, Shingen Nakamura³, Hirokazu Miki⁵, Itsuro Endo³, Eiji Tanaka¹, Toshio Matsumoto⁶, Masahiro Abe³ (1.Department of Hematology, Endocrinology and Metabolism, Tokushima Univ., Tokushima, Japan, 2.Department of Orthodontics and Dentofacial Orthopedics, Tokushima Univ., Tokushima, Japan, 3.Department of Hematology, Endocrinology and Metabolism, Tokushima Univ, Tokushima, Japan, 4.Department of Histology and Oral Histology, Tokushima Univ, Tokushima, Japan, 5.Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan, 6.Fujii Memorial Institute of Medical Sciences, Tokushima Univ, Tokushima, Japan)